424 related articles for article (PubMed ID: 22327882)
21. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells.
Sasidharan Nair V; Elkord E
Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507
[TBL] [Abstract][Full Text] [Related]
22. Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses.
Hoelzinger DB; Smith SE; Mirza N; Dominguez AL; Manrique SZ; Lustgarten J
J Immunol; 2010 Jun; 184(12):6833-42. PubMed ID: 20483762
[TBL] [Abstract][Full Text] [Related]
23. FoxP3
Saleh R; Elkord E
Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
[TBL] [Abstract][Full Text] [Related]
24. Targeting regulatory T cells for improving cancer therapy: Challenges and prospects.
Dwarakanath BS; Farooque A; Gupta S
Cancer Rep (Hoboken); 2018 Jun; 1(1):e21105. PubMed ID: 32729245
[TBL] [Abstract][Full Text] [Related]
25. Induced regulatory T cells in inhibitory microenvironments created by cancer.
Whiteside TL
Expert Opin Biol Ther; 2014 Oct; 14(10):1411-25. PubMed ID: 24934899
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of phosphoantigen-mediated gammadelta T-cell proliferation by CD4+ CD25+ FoxP3+ regulatory T cells.
Kunzmann V; Kimmel B; Herrmann T; Einsele H; Wilhelm M
Immunology; 2009 Feb; 126(2):256-67. PubMed ID: 18775028
[TBL] [Abstract][Full Text] [Related]
27. Regulatory T cell depletion enhances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-1b in hepatocellular carcinoma patients, in vitro.
Zhang HH; Mei MH; Fei R; Liao WJ; Wang XY; Qin LL; Wang JH; Wei L; Chen HS
Int J Oncol; 2010 Apr; 36(4):841-8. PubMed ID: 20198327
[TBL] [Abstract][Full Text] [Related]
28. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.
Pallandre JR; Brillard E; Créhange G; Radlovic A; Remy-Martin JP; Saas P; Rohrlich PS; Pivot X; Ling X; Tiberghien P; Borg C
J Immunol; 2007 Dec; 179(11):7593-604. PubMed ID: 18025205
[TBL] [Abstract][Full Text] [Related]
29. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T
Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102
[TBL] [Abstract][Full Text] [Related]
30. Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression.
Hiura T; Kagamu H; Miura S; Ishida A; Tanaka H; Tanaka J; Gejyo F; Yoshizawa H
J Immunol; 2005 Oct; 175(8):5058-66. PubMed ID: 16210609
[TBL] [Abstract][Full Text] [Related]
31. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
Jacobs JF; Nierkens S; Figdor CG; de Vries IJ; Adema GJ
Lancet Oncol; 2012 Jan; 13(1):e32-42. PubMed ID: 22225723
[TBL] [Abstract][Full Text] [Related]
32. MHC Class II Antigen Presentation by Lymphatic Endothelial Cells in Tumors Promotes Intratumoral Regulatory T cell-Suppressive Functions.
Gkountidi AO; Garnier L; Dubrot J; Angelillo J; Harlé G; Brighouse D; Wrobel LJ; Pick R; Scheiermann C; Swartz MA; Hugues S
Cancer Immunol Res; 2021 Jul; 9(7):748-764. PubMed ID: 33952631
[TBL] [Abstract][Full Text] [Related]
33. Significance of regulatory T cells in cancer immunology and immunotherapy.
Sugiyama D; Hinohara K; Nishikawa H
Exp Dermatol; 2023 Mar; 32(3):256-263. PubMed ID: 36458459
[TBL] [Abstract][Full Text] [Related]
34. Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target.
Hashemi V; Maleki LA; Esmaily M; Masjedi A; Ghalamfarsa G; Namdar A; Yousefi M; Yousefi B; Jadidi-Niaragh F
Int Immunopharmacol; 2020 Jan; 78():106087. PubMed ID: 31841758
[TBL] [Abstract][Full Text] [Related]
35. Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy.
Dees S; Ganesan R; Singh S; Grewal IS
Eur J Immunol; 2021 Feb; 51(2):280-291. PubMed ID: 33302322
[TBL] [Abstract][Full Text] [Related]
36. Regulatory T cells in cancer immunotherapy.
Tanaka A; Sakaguchi S
Cell Res; 2017 Jan; 27(1):109-118. PubMed ID: 27995907
[TBL] [Abstract][Full Text] [Related]
37. Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses.
Chen YL; Chang MC; Chen CA; Lin HW; Cheng WF; Chien CL
PLoS One; 2012; 7(10):e47190. PubMed ID: 23082146
[TBL] [Abstract][Full Text] [Related]
38. Regulatory T cells in cancer immunotherapy.
Nishikawa H; Sakaguchi S
Curr Opin Immunol; 2014 Apr; 27():1-7. PubMed ID: 24413387
[TBL] [Abstract][Full Text] [Related]
39. IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy.
Zhu J; Liu JQ; Shi M; Cheng X; Ding M; Zhang JC; Davis JP; Varikuti S; Satoskar AR; Lu L; Pan X; Zheng P; Liu Y; Bai XF
JCI Insight; 2018 Apr; 3(7):. PubMed ID: 29618655
[TBL] [Abstract][Full Text] [Related]
40. Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma.
Mittal S; Marshall NA; Duncan L; Culligan DJ; Barker RN; Vickers MA
Blood; 2008 Jun; 111(11):5359-70. PubMed ID: 18305220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
